Author:
Tourki Bochra,Jia Minxue,Karampitsakos Theodoros,Vera Iset M,Arsenault Alyssa,Marlin Krystin,Perrot Carole Y,Allen Dylan,Farsaei Forouzandeh,Rutenberg David,Bandyopadhyay Debabrata,Restrepo Ricardo,Qureshi Muhammad R.,Patel Kapilkumar,Tzouvelekis Argyrios,Kapetanaki Maria,Juan-Guardela Brenda,Kim Kami,Benos Panayiotis V,Herazo-Maya Jose D.
Abstract
AbstractBackgroundWe aim to study the source of circulating immune cells expressing a 50-gene signature predictive of COVID-19 and IPF mortality.MethodsWhole blood and Peripheral Blood Mononuclear cells (PBMC) were obtained from 231 subjects with COVID-19, post-COVID-19-ILD, IPF and controls. We measured the 50-gene signature (nCounter, Nanostring), interleukin 6 (IL6), interferon γ-induced protein (IP10), secreted phosphoprotein 1 (SPP1) and transforming growth factor beta (TGF-β) by Luminex. PCR was used to validate COVID-19 endotypes. For single-cell RNA sequencing (scRNA-seq) we used Chromium Controller (10X Genomics). For analysis we used the Scoring Algorithm of Molecular Subphenotypes (SAMS), Cell Ranger, Seurat, Propeller, Kaplan-Meier curves, CoxPH models, Two-way ANOVA, T-test, and Fisher’s exact.ResultsWe identified three genomic risk profiles based on the 50-gene signature, and a subset of seven genes, associated with low, intermediate, or high-risk of mortality in COVID-19 with significant differences in IL6, IP10, SPP1 and TGFβ-1. scRNA-seq identified Monocytic-Myeloid-Derived Suppressive cells (M-MDSCs) expressing CD14+HLA DRlowCD163+and high levels of the 7-gene signature (7Gene-M-MDSC) in COVID-19. These cells were not observed in post-COVID-19-ILD or IPF. The 43-gene signature was mostly expressed in CD4 T and CD8 T cell subsets. Increased expression of the 43 gene signature was seen in T cell subsets from survivors with post-COVID-19-ILD. The expression of these genes remained low in IPF.ConclusionA 50-gene, high-risk profile in COVID-19 is characterized by a genomic imbalance in monocyte and T-cell subsets that reverses in survivors with post-COVID-19 Interstitial Lung Disease
Publisher
Cold Spring Harbor Laboratory
Reference40 articles.
1. Guan, W.-j. , et al., Clinical Characteristics of Coronavirus Disease 2019 in China. New England Journal of Medicine, 2020.
2. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months;N Engl J Med,2021
3. Post-COVID-19 interstitial lung disease: Insights from a machine learning radiographic model;Front Med (Lausanne,2022
4. Commonalities Between ARDS, Pulmonary Fibrosis and COVID-19: The Potential of Autotaxin as a Therapeutic Target;Front Immunol,2021
5. Lung fibrosis: an undervalued finding in COVID-19 pathological series;Lancet Infect Dis,2021
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献